Faron press release February 23:
TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherapies, today announces that data from its Phase I/II BEXMAB trial evaluating bexmarilimab in combination with azacitidine for the treatment of higher-risk myelodysplastic syndromes (MDS) have been accepted for presentation at the 66th Annual Scientific Meeting of the British Society for Haematology (BSH), taking place 19–21 April 2026 in Liverpool, UK.
Do I understand correctly that the poster specifies: (presenting author)
Dr Emma Searle The Christie NHS Foundation Trust and the University of Manchester
AND that no Faron personnel are at least featured?
It would be worth starting to look for the abstract matching the title since the conference starts today.
BSH. Nothing particularly new. At least in one image, the data cut is 3.11.2025. Duration of response is good, but not revolutionary. For some, follow-up is still not complete. R/r MDS non-TP53 mOS was, for example, not determinable, median follow-up 11.8 months. These can be good things, with reservations. The response rate is good, especially in TP53. Patient cohorts are small, and censoring those who reached bone marrow transplant weakens the conclusions, i.e., shortens the follow-up of positive outcomes, so it’s the same old story: waiting for randomized results regarding responses (and their duration) and quality of life (blood transfusions, infections, etc.).
And it will be interesting to see how the success of those who made it to transplant is handled. According to Zeidan, for example, that was one possible benefit of venetoclax when the failed Verona trial was analyzed post-mortem—to see if there was any benefit in addition to the adverse effects. If that phenomenon could be utilized “pre-mortem” for Bex, now that the whole BEXERA is being considered from a new perspective.
